Search

// Luana Mota Martins 1 , Carla Solange de Melo Escorcio Dourado 1 , Larysse Maira Campos-Verdes 1 , Fabiane Araujo Sampaio 1 , Camila Maria Simplicio Revoredo 1 , Danylo Rafhael Costa-Silva 1 , Maria da Conceicao Barros-Oliveira 1 , Elmo de Jesus Nery Junior 1 , Lucia Maria do Rego-Medeiros 2 , Luiz Henrique Gebrim 1 , Francisco Adelton Alves-Ribeiro 1 , Gilmara Peres Rodrigues 1 , Diego Cipriano Chagas 1 , Dilina do Nascimento Marreiro 1 and Benedito Borges da Silva 1 , 2 1 Postgraduate Program, Northeast Biotechnology Network (RENORBIO), Biotechnology in Health, Federal University of Piaui, Teresina, Piaui 64000-020, Brazil 2 Facid / Wyden Differential Integral Medicine Faculty, Department of Mastology, Teresina, Piaui 64052-810, Brazill Correspondence to: Benedito Borges da Silva, email: beneditoborges@globo.com Keywords: breast neoplasms; fibroadenoma; matrix metalloproteinase-2; matrix metalloproteinase-9; immunohistochemistry Received: September 17, 2019 Accepted: November 06, 2019 Published: December 03, 2019 ABSTRACT Background Matrix metalloproteinases (MMPs) 2 and 9 may play an important role in cell proliferation and dissemination of cancer. However, few studies have compared the expression of these proteins between breast cancer and fibroadenoma. Material and methods A randomized, double-blind study was carried out in 66 premenopausal women, aged 20-49 years, who had been diagnosed with fibroadenoma or breast cancer. The patients were divided into two groups: Group A, control (fibroadenoma, n=36) and Group B, study (cancer, n=30). Immunohistochemical analysis was performed using tissue samples of fibroadenoma and breast cancer to assess MMP-2 and MMP-9 antigen expression. Cells were considered positive if exhibiting brown cytoplasmic staining. Fisher’s exact test was used to compare the percentage of cases with cells expressing MMP-2 and MMP-9 in control and study groups (p < 0.05). Results Light microscopy showed a higher concentration of cells with positive cytoplasmic staining for MMP-2 and MMP-9 expression in breast cancer than in fibroadenoma. The percentage of cases with cells expressing MMP-2 in the control and study groups was 41.67% and 86.11%, respectively (p < 0.0009), whereas the percentage of cases with cells expressing MMP-9 in groups A and B was 66.67% and 93.33%, respectively (p

Gliomas are the most common primary tumors of the central nervous system with unclear etiology. However, hereditary factors may play an important role in glioma development, with mutations and single nucleotide polymorphisms (SNPs) being prominent among the genetic changes. This study aimed to evaluate the association of the ERCC2 gene rs13181 variant polymorphism between high- and low-grade gliomas in patients from Brazil’s Northeast region. Samples from glioma patients stored in paraffin blocks were used. DNA extraction was performed using the MagMAX™ FFPE DNA/RNA Ultra kit, and for genotyping, the Taqman assay probe C_3145033_10 corresponding to the SNP rs13181 of the ERCC2 gene was selected. Quantitative and categorical variables were analyzed using the t-test and Fisher’s exact test or Chi-square test (p p = 0.003). Statistically significant differences were not observed in the expression of the GG, GT, and TT genotypes between low- and high-grade gliomas. The ERCC2 rs13181 genotypes found were TT, GG, and GT; however, no difference in the expression between different glioma types was observed.

BackgroundGliomas are the most common primary tumors of the central nervous system with unclear etiology, however hereditary factors may play important roles in the development of gliomas with mutations and single nucleotide polymorphisms (SNPs) being prominent among the genetic changes. this systematic review and meta-analysis assess the association of XRCC1 (rs1799782) and ERCC2 (rs13181) gene polymorphisms and glioma risk.MethodsThis study included articles indexed in the PUBMED and EMBASE databases published during the past 15 years. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. The PICOS model was used to develop the inclusion criteria and search terms. This review was recorded at PROSPERO International prospective register of systematic reviews, ID 196173. The META-MAR V2.7.0 meta-analysis calculator was used for the statistical analysis with p-values < 0.05 being considered statistically significant. Dichotomous data are presented as odds ratios (OR) with a 95% confidence interval (CI). Statistical heterogeneity was measured using the I2 test and I2 > 50% were regarded as high heterogeneity. Funnel plots, Begg (BT) and Egger Tests (ET) were used to assess publication bias (pResults Literature review identified 10 articles on ERCC2 gene rs13181 variant and 11 on XRCC1 rs1799782. The meta-analysis identified a risk for gliomas for the TT genotype of the XRCC1 rs1799782 SNP in Asians (OR: 1.59, 95% CI: 1.3-1.93; p=0.006; I2 13.1%). ERCC2 rs13181 polymorphisms identified as risks for gliomas were AC genotypes in Asians (OR: 2.06, 95% CI: 1.75-1.42; p = 0.00057; I2 91.1%) and Caucasians (OR: 1.16, 95% CI: 1.01-1.31; p = 0.02; I2 12.2%), and CC genotypes in Caucasians (OR: 2.06, 95% CI: 1.75-1.42; p = 0.0001; I2 98.9%).Conclusions TT genotypes of the XRCC1 rs1799782 SNP in Asians, AC genotypes of ERCC2 rs13181 polymorphisms in Asians and Caucasians, and CC genotypes of ERCC2 rs13181 polymorphisms in Caucasians were associated with increased risk for gliomas that may benefit these patients with early diagnostic and therapeutic strategies.